Previous 10 | Next 10 |
AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) today announced its OVA1 ® risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health’s Clinical Appr...
AUSTIN, Texas, June 03, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease, released the analytical and initial clinical data for OVASight™ in an abstract titled ȁ...
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Summer Solstice - Best Ideas fro...
AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for ...
Image source: The Motley Fool. Aspira Women's Health Inc. (NASDAQ: AWH) Q1 2021 Earnings Call May 13, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Aspira Women's Health Inc. (AWH) Q1 2021 Earnings Call Transcript...
Aspira Women's Health Inc. (AWH) Q1 2021 Results Conference Call May 13, 2021 04:30 PM ET Company Participants Valerie Palmieri - President and CEO Bob Beechey - CFO Kaile Zagger - COO Dr. Lesley Northrop - Chief Scientific Officer Dr. Elena Ratner - Global Chief Medical Advisor and Clinical ...
Aspira Women’s Health (AWH): Q1 GAAP EPS of -$0.05 beats by $0.12.Revenue of $1.49M (+22.1% Y/Y) beats by $0.12M.Press Release For further details see: Aspira Women’s Health EPS beats by $0.12, beats on revenue
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. ...
- Analytical and Initial Clinical Validation performance for Aspira’s OVASight™ blood-based biomarker test for Ovarian Malignancy risk assessment in women with Adnexal Masses. - Data demonstrates the ability to identify Ovarian Cancer Risk i...
AUSTIN, Texas, May 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on gynecologic disease and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, the largest privat...
News, Short Squeeze, Breakout and More Instantly...
Aspira Women's Health Inc. Company Name:
AWH Stock Symbol:
NASDAQ Market:
Aspira Women's Health Inc. Website:
Preliminary OvaWatch ® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuite SM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units AUSTIN, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Heal...
AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that i...
AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has...